DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Nuclear Medicine Market - Growth, Trends & Forecasts (2015-2020)" report to their offering.
The Global Nuclear medicine market has been estimated to be valued at USD 11.04 Billion for the year 2015 and the market is expected to hit USD 19.4 billion by the year 2020 at a CAGR of 12.3%. The market is set to be mostly driven by the therapeutic radio pharmaceuticals, which are expected to grow at CAGR of 30% during 2015 to 2020.
Though in existence since the 1940s the nuclear medicine market came to the forefront only in the past decade mostly due to the emergence of new radio nucleotides and the number of products under development has grown since then, at an increasing pace. Nuclear medicine has applications in the fields of cardiology, lymphoma, thyroid, neurology oncology, and others.
Increasing incidences of cancer and cardiac ailments, Increasing awareness for radiopharmaceuticals, and ready availability of radiopharmaceuticals are the major driving forces for this market. Increased public awareness and use of Radio diagnostic techniques such as SPECT and PET also fuel the market growth. Some of the major constraints for the market are shorter half- life of radioisotopes, high capital investment, regulatory guidelines and reimbursement issues.
The radiopharmaceutical market is broadly classified into two segments, namely diagnostic and therapeutic.
- Covidien Plc
- GE Healthcare
- IBA Group
- Lantheus Medical Imaging Inc.
- Nordion Inc.
Siemens Healthcare (PETNET)
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Company Profiles
10. Analyst Outlook for Investment Opportunities
11. Future Outlook of the Market
For more information about this report visit http://www.researchandmarkets.com/research/b823fc/global_nuclear